New treatment to protect brain cells during a stroke
Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke
This study is testing a new treatment that aims to protect brain cells during a stroke, which could help improve recovery and reduce long-term disability for stroke patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Celdara Medical, LLC NIH-funded |
| Lab location | 1 site (Lebanon, United States) |
| Project ID | NIH-10932426 on NIH RePORTER |
What this research studies
This research focuses on developing a novel neuroprotective therapy aimed at preserving brain cells during an acute ischemic stroke (AIS). The approach involves targeting a specific signaling pathway that leads to neuronal cell death, with the goal of preventing damage in the brain's ischemic penumbra, the area surrounding the stroke-affected region. The lead compound, CM-EA1, is designed to be administered alongside existing treatments like alteplase, potentially improving outcomes for stroke patients. By enhancing the preservation of brain tissue, this therapy could significantly reduce long-term disability associated with strokes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing an acute ischemic stroke who are within the therapeutic time window for treatment.
Not a fit: Patients who have already suffered irreversible brain damage or are outside the treatment window may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that minimizes brain damage and improves recovery for stroke patients.
How similar studies have performed: While the approach of targeting neuronal cell death pathways is promising, it is relatively novel and has not been extensively tested in human trials for stroke treatment.
Where this research is happening
Lebanon, United States
- Celdara Medical, LLC — Lebanon, United States (Active)
Researchers
- Principal investigator: Coleman, Julie H — Celdara Medical, LLC
- Study coordinator: Coleman, Julie H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.